Fig. 5.

S217879 reduced NASH progression and liver fibrosis in DIO NASH mice model.

(A) Body weight at the end of the study. (B) Liver weight expressed as percentage of total body weight. (C) Plasma ALT levels. (D) Plasma AST levels. (E) Liver TGs. (F) Liver Gal3-positive area. Data expressed as mean ± SEM (n = 14 per group). (G) H&E and PSR-stained liver sections. (H) Summary of histopathological NAFLD activity (left graph) scoring and fibrosis stage (left graph) of pre- and post-study biopsies. For each group, the number of animals with a higher (worsening), same or lower (improvement) score at post- compared to pre-study is indicated by the height of the bar. (A-F) Significant differences were analyzed using Student’s t test. (H) Significance of number of animals with a lower score vs. vehicle was assessed using Fisher’s exact test followed by correction for multiple comparisons using the Bonferroni method. ∗∗∗p <0.001, ∗∗p <0.01 and ∗p <0.05: S217879-treated vs. vehicle.